Trial Profile
Multiple-dose, Double-blind, Double-dummy Study to Compare the Efficacy and Safety of Oral Doses of Cinacalcet Hydrochloride With Intravenous Doses of Etelcalcetide) in Asian Hemodialysis Subjects With Secondary Hyperparathyroidism
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Etelcalcetide (Primary) ; Cinacalcet
- Indications Secondary hyperparathyroidism
- Focus Therapeutic Use
- Sponsors Amgen
- 13 Apr 2020 Status changed from active, no longer recruiting to completed.
- 25 Feb 2020 Status changed from recruiting to active, no longer recruiting.
- 20 Dec 2018 Planned End Date changed from 26 Nov 2019 to 13 Apr 2020.